RUNX2 is a key regulator of bone development and it controls genes that contribute to cell growth regulation in osteoblast. This study investigated the role that RUNX2 play in the cell proliferation regulatory pathways of breast cancer cells. From our serum stimulation study of MDA-MB-231 cells, results showed that RUNX2 protein levels decreased and proliferation of breast cancer cells was enhanced. Our quantitative RT-PCR results showed approximately 5-fold higher levels of cyclin D1 in MDA-MB-231 cells with knockdown of RUNX2; further suggest the involvement of RUNX2 in inhibiting cell proliferation. ERK pathway is the best characterized MAPK pathway in mammalian cells, which plays a key role in cell proliferation. From our study, we show...
Runt-related transcription factors (RUNXs) can serve as both transcription activators and repressors...
Runt-related transcription factors (RUNXs) can serve as both transcription activators and repressors...
Breast cancer remains the most common malignant disease in women worldwide. Despite the advantages o...
RUNX2 is a transcription factor playing the major role in osteogenesis, but it can be involved in DN...
Human breast cancers are known to preferentially metastasize to the skeletal sites and the osteolyti...
Background Runx2 is one of the runt-related genes that are overexpressed in human cancers and contri...
INTRODUCTION: Metastatic breast cancer cells frequently and ectopically express the transcription fa...
PURPOSE: The runt-related transcription factor, Runx2 may have an oncogenic role in mediating metast...
The three mammalian Runt homology domain transcription factors (Runx1, Runx2, Runx3) support biologi...
The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serio...
The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serio...
RUNX2, a master regulator of osteogenesis, is oncogenic in the lymphoid lineage; however, little is ...
Runx1 is a transcription factor essential for definitive hematopoiesis, and genetic abnormalities in...
Breast cancer (BrCa) remains the leading cause of cancer-related deaths in women worldwide. Current ...
Regulators of differentiated cell fate can offer targets for managing cancer development and progres...
Runt-related transcription factors (RUNXs) can serve as both transcription activators and repressors...
Runt-related transcription factors (RUNXs) can serve as both transcription activators and repressors...
Breast cancer remains the most common malignant disease in women worldwide. Despite the advantages o...
RUNX2 is a transcription factor playing the major role in osteogenesis, but it can be involved in DN...
Human breast cancers are known to preferentially metastasize to the skeletal sites and the osteolyti...
Background Runx2 is one of the runt-related genes that are overexpressed in human cancers and contri...
INTRODUCTION: Metastatic breast cancer cells frequently and ectopically express the transcription fa...
PURPOSE: The runt-related transcription factor, Runx2 may have an oncogenic role in mediating metast...
The three mammalian Runt homology domain transcription factors (Runx1, Runx2, Runx3) support biologi...
The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serio...
The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serio...
RUNX2, a master regulator of osteogenesis, is oncogenic in the lymphoid lineage; however, little is ...
Runx1 is a transcription factor essential for definitive hematopoiesis, and genetic abnormalities in...
Breast cancer (BrCa) remains the leading cause of cancer-related deaths in women worldwide. Current ...
Regulators of differentiated cell fate can offer targets for managing cancer development and progres...
Runt-related transcription factors (RUNXs) can serve as both transcription activators and repressors...
Runt-related transcription factors (RUNXs) can serve as both transcription activators and repressors...
Breast cancer remains the most common malignant disease in women worldwide. Despite the advantages o...